A Phase 2 Randomized Open-Label Controlled Study to Evaluate the Efficacy and Safety of Ampligen in Combination With Standard of Care Versus SOC Alone Following First-Line Therapy in Subjects With Locally Advanced Pancreatic Adenocarcinoma

The purpose of this study is to assess the safety and efficacy of Ampligen in patients with locally advanced pancreatic adenocarcinoma

开始日期2024-12-01

申办/合作机构

AIM ImmunoTech, Inc.

[+1]

NCT04093323

/ Recruiting临床2期IIT

A Phase II Study of Type-1 Polarized Dendritic Cell (aDC1) -Based Treatment in Combination With Tumor-Selective Chemokine Modulation (CKM: Interferon Alpha 2b, Rintatolimod and Celecoxib) in Melanoma Patients With Primary PD-1/PD-L1 Resistance

This phase II trial studies how well polarized dendritic cell (aDC1) based therapy, interferon alpha-2, rintatolimod, and celecoxib work together in treating patients with HLA-A2 positive (+) melanoma that has not responded to previous treatment (refractory). The aDC1 cell-based treatment contains white blood cells (dendritic cells or DCs) that stimulates the immune system. Interferon alpha-2 can improve the body's natural response to infections and other diseases. It can also interfere with the division of cancer cells and slow tumor growth. Rintalolimid may stimulate the immune system. Celecoxib is a drug that reduces pain. This study is being done to find out if the combination of the study cell-based treatment (aDC1 dendritic cells) and interferon alpha-2, rintatolimod, and celecoxib can prevent the growth and/or progression of melanoma.

开始日期2024-11-13

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

NCT05756166

/ Recruiting临床1/2期IIT

Phase I/IIa Clinical Trial Evaluating the Safety and Efficacy of Rintatolimod Combined With IFNα2b (Bioferon®) to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast Cancer

This phase I/IIa trial tests the safety, side effects, and best dose of chemokine modulation therapy (CKM) (rintatolimod, celecoxib, and interferon alpha 2b) in combination with pembrolizumab for the treatment of patients with triple negative breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) or that cannot be removed by surgery (unresectable). CKM drugs such as rintatolimod and interferon alpha 2b work to modify the immune response and tumor-related processes, including tumor cell growth, blood vessel growth, and metastasis. Celecoxib is an anti-inflammatory drug that can cause cell death and may reduce the growth of blood vessels tumors need to grow and spread. Immunotherapy such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving CKM therapy prior to pembrolizumab may direct the immune cells to the cancer cells and maximize the effectiveness of pembrolizumab in patients with metastatic or unresectable triple negative breast cancer.

开始日期2024-02-16

申办/合作机构

Roswell Park Comprehensive Cancer Center

[+1]

100 项与安普利近相关的临床结果

登录后查看更多信息

100 项与安普利近相关的转化医学

登录后查看更多信息

100 项与安普利近相关的专利（医药）

登录后查看更多信息

项与安普利近相关的文献（医药）

2024-11-01·Journal for ImmunoTherapy of Cancer

Systemic chemokine-modulatory regimen combined with neoadjuvant chemotherapy in patients with triple-negative breast cancer

Article

作者: Attwood, Kristopher ; Wang, Jianming ; Gnjatic, Sacha ; Ioannou, Giorgio ; De Souza, Igor ; Fitzpatrick, Victoria ; Kumar, Prasanna ; Miller, Janine ; Janes, Cayla ; Kokolus, Kathleen M ; Kalinski, Pawel ; Gandhi, Shipra ; Opyrchal, Mateusz ; Young, Jessica ; O’Connor, Tracey ; O'Connor, Tracey ; Roudko, Vladimir ; Levine, Ellis G ; Slomba, Ronald T ; Cortes Gomez, Eduardo ; Kalathil, Suresh ; Cappuccino, Helen ; Ozbey, Sinem ; Takabe, Kazuaki ; Edge, Stephen

Background:

Higher cytotoxic T lymphocyte (CTL) numbers in the tumor microenvironment (TME) predict pathologic complete response (pCR) to neoadjuvant chemotherapy (NAC) and positive long-term outcomes in triple-negative breast cancer (TNBC). pCR to NAC is achieved only in 30–40% of patients. The combination of NAC with pembrolizumab increases the pCR rate but at the cost of immune-related adverse events (irAEs). Based on these considerations, we tested if systemic infusion of the chemokine modulatory regimen (CKM; selective toll-like receptor 3 (TLR3) agonist rintatolimod, interferon (IFN)-α2b, and cyclooxygenase-2 (COX-2) inhibitor celecoxib) regimen can be safely combined with NAC to enhance intratumoral CTL numbers and NAC effectiveness.

Methods:

Phase I studyNCT04081389evaluated nine patients with early-stage TNBC who received 3 weeks of paclitaxel with CKM (dose-escalation of IFN-α2b), followed by 9 weeks of paclitaxel alone, dose-dense doxorubicin and cyclophosphamide, and surgery. Primary and secondary endpoints were safety and clinical efficacy, respectively.

Results:

The combination treatment was well-tolerated with no dose-limiting toxicities or irAEs. 5/9 patients achieved pCR and one patient had microinvasive disease (ypTmic). We observed elevated IFN signature and uniform decreases in CTL numbers (average 8.3-fold) in the blood of all treated patients. This was accompanied by reciprocal uniform increases in CD8β (overall 5.9-fold), CD8α/FoxP3 (2.11-fold), and CCL5 (4.73-fold) transcripts in TME, particularly pronounced in patients with pCR. Multiplex immunohistochemistry revealed selectively increased numbers of CTL (but not regulatory T cells) in both the epithelial and stromal tumor compartments and early decreases in the numbers of αSMA+vascular/stromal cells in the tumors of all pCR patients.

Conclusions:

Combined paclitaxel/CKM regimen was safe, with desirable TME changes and preliminary indications of promising pCR+ypTmic of 66%, comparable to the combination of NAC with pembrolizumab.

2024-08-15·Clinical cancer research : an official journal of the American Association for Cancer Research

Rintatolimod in Advanced Pancreatic Cancer Enhances Antitumor Immunity through Dendritic Cell–Mediated T-Cell Responses

Article

作者: van Eijck, Casper H.J. ; van Eijck, Casper W.F. ; Mustafa, Dana A.M. ; Aerts, Joachim G.J.V. ; Kucukcelebi, Songul ; Willemsen, Marcella ; Fellah, Amine ; Vadgama, Disha ; Haddaoui, Hassana el

Abstract:

Purpose::

Amid the need for new approaches to improve survival in pancreatic ductal adenocarcinoma (PDAC), immune-based therapies have garnered interest. Rintatolimod, a Toll-like receptor 3 (TLR-3) agonist, is a potential candidate due to its dual impact on restraining PDAC cell functions and boosting the antitumor immune response. This study investigates the effect of TLR-3 activation through rintatolimod on the peripheral immune landscape of patients with advanced PDAC.

Experimental Design::

Paired blood samples of 30 patients with advanced PDAC, collected at baseline and after 12 rintatolimod intravenous infusions, underwent comprehensive transcriptomic NanoString and proteomic flow cytometry profiling. The impact of rintatolimod and immunologic factors on survival outcomes was assessed through univariate Cox proportional hazards models.

Results::

Rintatolimod treatment enhances peripheral immune activity at the transcriptomic and proteomic levels, particularly involving type 1 conventional dendritic cells (cDC1) and T cells. Post-rintatolimod, the increased peripheral abundance of BTLA+ XCR1+ cDC1s and CD4+SELL+ T cells correlated with improved clinical outcomes. Patients with stable disease exhibited pronouncedDCand T-cell activation gene overexpression. Notably, the expression of immune checkpoints PD-L1 and PD-L2 decreased post-rintatolimod across all patients. However, those with progressive disease showed increased expression of genes encoding IDO1 and PD-1.

Conclusions::

This study presents compelling evidence of the immune-stimulatory properties linked to TLR-3 activation through rintatolimod. Rintatolimod may break immunologic tolerance by enhancing antitumor immunity through DC-mediated Th-cell responses. Furthermore, our findings lay the groundwork for investigating the potential synergy between TLR-3 activation and immune checkpoint inhibitor therapy to improve therapeutic outcomes.See related commentary by Martínez-Riaño et al., p. 3355

2023-11-01·Journal for immunotherapy of cancer

Systemic infusion of TLR3-ligand and IFN-α in patients with breast cancer reprograms local tumor microenvironments for selective CTL influx

Article

作者: Kokolus, Kathleen M ; Attwood, Kristopher ; Wallace, Paul K ; Grimm, Melissa J ; Slomba, Ronald T ; Witkiewicz, Agnieszka ; O'Connor, Tracey L ; Minderman, Hans ; Williams, Lauren ; Groman, Adrienne ; Levine, Ellis G ; Kalinski, Pawel ; Soh, Kah Teong ; Early, Amy P ; Maguire, Orla ; Opyrchal, Mateusz ; Tarquini, Mary Lynne ; Gandhi, Shipra

Background:

Presence of cytotoxic T lymphocytes (CTL) in the tumor microenvironment (TME) predicts the effectiveness of cancer immunotherapies. The ability of toll-like receptor 3 (TLR3) ligands, interferons (IFNs) and COX2 inhibitors to synergistically induce CTL-attracting chemokines (but not regulatory T cell (Treg)-attractants) in the TME, but not in healthy tissues, observed in our preclinical studies, suggested that their systemic application can reprogram local TMEs.

Methods:

Six evaluable patients (33–69 years) with metastatic triple-negative breast cancer received six doses of systemic chemokine-modulating (CKM) regimen composed of TLR3 ligand (rintatolimod; 200 mg; intravenous), IFN-α2b (20 MU/m2; intravenous) and COX2 inhibitor (celecoxib; 2×200 mg; oral) over 2 weeks. The predetermined primary endpoint was the intratumoral change in the expression of CTL marker, CD8α, in the post-CKM versus pre-CKM tumor biopsies. Patients received follow-up pembrolizumab (200 mg, intravenously, every 3 weeks), starting 3–8 days after completion of CKM.

Results:

Post-CKM biopsies showed selectively increased CTL markers CD8α (average 10.2-fold, median 5.5-fold, p=0.034) and granzyme B (GZMB; 6.1-fold, median 5.8-fold, p=0.02), but not FOXP3 (Treg marker) relative to HPRT1 expression, resulting in the increases in average CD8α/FOXP3 ratio and GZMB/FOXP3 ratio. CKM increased intratumoral CTL-attractants CCL5 and CXCL10, but not Treg-attractants CCL22 or CXCL12. In contrast, CD8+T cells and their CXCR3+subset showed transient decreases in blood. One clinical response (breast tumor autoamputation) and three stable diseases were observed. The patient with clinical response remains disease free, with a follow-up of 46 months as of data cut-off.

Conclusions:

Short-term systemic CKM selectively increases CTL numbers and CTL/Treg ratios in the TME, while transiently decreasing CTL numbers in the blood. Transient effects of CKM suggest that its simultaneous application with checkpoint blockade and other forms of immunotherapy may be needed for optimal outcomes.

133

项与安普利近相关的新闻（医药）

2025-01-20

·GlobeNewswire-Health Care

AIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving Milestones

– Continued execution across Ampligen® (rintatolimod) clinical development programs in areas with critical unmet needs, especially in the high-value pancreatic cancer and Long-COVID spaces – Expected milestones over the course of the next 18 months provide significant value-driving opportunities, including some trials being partially funded by the National Cancer Institute, AstraZeneca and Merck Jan. 15, 2025 -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today highlighted key clinical, regulatory and corporate milestones achieved over 2024 and outlined its expected upcoming milestones. “It is clear that 2024 was a foundational year for AIM on the clinical, regulatory and corporate fronts. Without a doubt, our team continued to drive our strategy forward and deliver results. We believe this progress has positioned AIM for an exciting 2025 and the opportunity to drive value for our stockholders,” stated Thomas K. Equels, Chief Executive Officer of AIM ImmunoTech. “Looking ahead, we believe we are poised for an exciting 2025 with a number of key milestones expected over the next 18 months across important clinical trials addressing major unmet medical needs. Certain of these trials are being funded in part by major oncology interests such as the National Cancer Institute, AstraZeneca and Merck, which we believe emphasizes their great potential to change lives for the better. Our team is committed to the seamless execution of our clinical development programs and, if successful, we believe each holds the potential to drive significant value in the near and long term.” Metastatic Pancreatic Ductal Adenocarcinoma Program Commenced enrollment and dosing in DURIPANC Phase 1b/2 study combining Ampligen with AstraZeneca’s anti-PD-L1 immune checkpoint inhibitor Imfinzi® (durvalumab) for the treatment of late-stage pancreatic cancer; Announced that the first dose level was generally well-tolerated in the DURIPANC Phase 1b/2 study of Ampligen and Imfinzi as a combination therapy for late-stage pancreatic cancer; and Reported positive preliminary data from Phase 1b/2 study of Ampligen and Imfinzi as a combination therapy for late-stage pancreatic cancer. Phase 2 Locally Advanced Pancreatic Adenocarcinoma Program Received authorization from the Erasmus Medical Center Ethics Committee to open a European site for the ongoing Phase 2 study (“AMP-270”) of Ampligen as a therapy for locally advanced pancreatic cancer; and Announced the publication of new positive data analysis from a long-term Early Access Program studying Ampligen for the treatment of advanced pancreatic ductal adenocarcinoma. The Company sought FDA guidance on expansion of inclusion criteria and treatment arms, and then subsequently amended the study protocol. The study is recruiting patients. These adjustments are also expected to result in substantial reductions in clinical costs. Phase 2 Recurrent Ovarian Cancer Program Reported positive top-line, protocol-planned interim report data from the study of Ampligen combined with pembrolizumab for the treatment of recurrent ovarian cancer. Phase 2 Post-COVID Conditions Program Reported positive topline results from the Company’s Phase 2 study evaluating the efficacy and safety of Ampligen as a potential therapeutic for people with the post-COVID condition of fatigue (“AMP-518”); and Reported an analysis of the AMP-518 clinical trial, based upon statistically significant data, which supports the Company’s belief in Ampligen as a potential therapeutic for people with the moderate-to-severe post-COVID-19 condition of fatigue, and that this would be the likely subject population for AIM’s planned follow-up clinical trial. Further, the Company was also granted two important patents covering Ampligen for the treatment of: Endometriosis, a painful chronic condition that affects nearly 10% of women of reproductive age, or approximately 6.5 million women in the United States. This patent was granted in the United States. The Post-COVID Condition of Fatigue. This method and compositions patent was granted in the Netherlands. Additionally, AIM successfully completed cGMP manufacturing of 9,042 clinical vials of Ampligen. The Company announced the publication of new pre-clinical data of Ampligen as part of a combinational therapy in the treatment of melanoma. Metastatic Pancreatic Ductal Adenocarcinoma Phase 1b/2 Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab with TLR-3 Agonist Ampligen in Patients with Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy (DURIPANC) (NCT05927142); Funded through collaboration of AstraZeneca and Erasmus Medical Center Q1 2025: Complete Phase 1b Early Q2 2025: Launch of Phase 2 Q2/Q3 2026: Last patient enrolled in Phase 2 Locally Advanced Pancreas Cancer (LAPC) Phase 2 Ampligen Combined with Standard of Care (SOC) versus SOC Alone Following First-Line Therapy in Subjects with LAPC (NCT05494697); AIM funded Q1 2025: Buffet Cancer Center expected to enroll first subject H1 2025: first subject dosed Refractory Melanoma Phase 2 Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Ampligen, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma (NCT04093323); Grant funded by National Cancer Institute H1 2025: First patient dosed Stage 4 Triple Negative Breast Cancer Phase 1/2a Study of Ampligen, Celecoxib and Interferon Alpha 2b with Pembrolizumab for the Treatment of Patients with Metastatic or Unresectable Triple Negative Breast Cancer (NCT05756166); Grant funded by Merck and National Cancer Institute Q2 2026: Expected completion of enrollment Advanced Recurrent Ovarian Cancer Phase 2 Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer (NCT03734692); Grant funded by Merck H1 2025: Expected last patient dosed and completion of study Advanced Recurrent Ovarian Cancer Phase 2 Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines (NCT02432378); Grant funded by the National Cancer Institute H1 2025: First patient dosed Post COVID Chronic Fatigue Conditions / Long Covid Phase 2 Study to Evaluate the Efficacy and Safety of Ampligen in Patients with Post-COVID Conditions (NCT05592418); AIM funded Q1 2025: Final approved study results to be published on clinicaltrials.gov AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. The content above comes from the network. if any infringement, please contact us to modify.

免疫疗法临床结果疫苗

2024-12-17

·GlobeNewswire-Health Care

AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards

A Plan for Compliance has been UndertakenOCALA, Fla., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”), announced today that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated December 11, 2024, notifying the Company that it is no longer in compliance with NYSE American continued listing standards. This is an issue previously disclosed in our most recent Report on Form 10-Q. Specifically, the letter states that the Company is not in compliance with the continued listing standards set forth in Sections 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (the “Company Guide”). Section 1003(a)(ii) requires a listed company to have stockholders’ equity of $4 million or more if the listed company has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. Section 1003(a)(iii) requires a listed company to have stockholders’ equity of $6 million or more if the listed company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years. The Notice has no immediate impact on the listing of the Company’s shares of common stock, par value $0.001 per share (the “Common Stock”), which will continue to be listed and traded on the NYSE American during the period in which the Company implements its plan to become compliant with these NYSE American continued listing standards, subject to the Company’s compliance with the other listing requirements of the NYSE American. The Common Stock will continue to trade under the symbol “AIM”, but will have an added designation of “.BC” to indicate the status of the Common Stock as “below compliance”. The Notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission. The Company must submit a plan of compliance (the “Plan”) by January 10, 2025, addressing how it intends to regain compliance with Sections 1003(a)(ii) and (iii) of the Company Guide by June 11, 2026. The Company has begun to prepare its Plan for submission to the NYSE American by the January 10, 2025 deadline. If the NYSE American accepts the Company’s Plan, the Company will be able to continue its listing during its implementation of the Plan and will be subject to continued periodic review by the NYSE American staff. If the Plan is not submitted, or not accepted, or is accepted but the Company is not in compliance with the continued listing standards by June 11, 2026, or if the Company does not make progress consistent with the Plan during such period, the Company will be subject to delisting procedures as set forth in the Company Guide. The Company may appeal a staff delisting determination in accordance with Section 1010 and Part 12 of the Company Guide. About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook. Cautionary Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. There can be no assurance that the Company will be able to achieve compliance with the NYSE American’s continued listing standards within the required timeframe. The Company urges investors to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the U.S. Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

免疫疗法

2024-12-17

·Business Wire

AIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual Meeting

OCALA, Fla.--( BUSINESS WIRE )--AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that, based on the preliminary vote count of its proxy solicitor, shareholders have elected three of the Company’s incumbent directors – Nancy K. Bryan, Thomas K. Equels and Dr. William M. Mitchell – to the Board of Directors (the “Board”) at the 2024 Annual Meeting of Stockholders (the “Annual Meeting”) held today. Additionally, Ted D. Kellner was elected to the Board. Dr. William M. Mitchell, Chairman of the Board, stated: “ We would like to sincerely thank our shareholders for their support and engagement throughout this process and are grateful for their trust in our clinical development strategy. The AIM Board is fully committed to the Company’s success and the potential of our lead drug candidate, Ampligen. We are glad to put this proxy contest behind us and focus on supporting our high value cancer clinical development programs in areas with critical unmet needs. “ We would like to thank Stewart Appelrouth for his dedicated service on the Board. Additionally, we look forward to working constructively with Mr. Kellner in the boardroom as we pursue our significant opportunities with Ampligen and deliver significant long-term value for all shareholders.” The Company notes the requisite quorum of 40% of the Company’s outstanding shares entitled to vote was present at the Annual Meeting. The results announced today are considered preliminary until final results are tabulated and certified by the independent Inspector of Elections. Final results will be reported on a Form 8-K that will be filed with the Securities and Exchange Commission. *** About AIM ImmunoTech Inc. AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company’s lead product is a first-in-class investigational drug called Ampligen ® (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system. For more information, please visit aimimmuno.com and connect with the Company on X , LinkedIn , and Facebook . Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “PSLRA”). Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “continue,” “believe,” “potential,” “upcoming” and other variations thereon and similar expressions (as well as other words or expressions referencing future events or circumstances) are intended to identify forward-looking statements. Many of these forward-looking statements involve a number of risks and uncertainties. Data, pre-clinical success and clinical success seen to date does not guarantee that Ampligen will be approved as a treatment or therapy for any diseases or conditions. The Company urges investors to consider specifically the various risk factors identified in its most recent Annual Report on Form 10-K, and any risk factors or cautionary statements included in any subsequent Quarterly Report on Form 10-Q or Current Report on Form 8-K, filed with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Among other things, for those statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the PSLRA. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof.

高管变更

100 项与安普利近相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09661	安普利近	L03A	-

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
慢性疲劳综合征	阿根廷	AIM ImmunoTech, Inc.	2017-01-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
局部晚期胰腺腺癌	临床2期	美国	AIM ImmunoTech, Inc.	2024-12-01
转移性胰腺导管腺癌	临床2期	荷兰	AIM ImmunoTech, Inc.	2024-01-09
新冠肺炎后遗症	临床2期	美国	AIM ImmunoTech, Inc.	2023-06-30
结直肠癌	临床2期	-	AIM ImmunoTech, Inc.	2022-04-11
新型冠状病毒感染	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17
血液肿瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17
恶性实体肿瘤	临床2期	美国	Roswell Park Comprehensive Cancer Center	2020-11-17
前列腺腺癌	临床2期	美国	AIM ImmunoTech, Inc.	2019-11-29
遗传性前列腺癌7型	临床2期	美国	AIM ImmunoTech, Inc.	2019-11-29
流感病毒感染	临床2期	美国	AIM ImmunoTech, Inc.	2012-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05592418 (AMP-518, CTgov)	临床2期	新冠肺炎后遗症	80	Rintatolimod (Ampligen / Rintatolimod)	醖鑰遞構繭壓製蓋鑰窪(鏇製鑰鹹構遞憲醖鬱窪) = 製壓糧簾製鏇餘醖鑰夢築鏇壓淵範顧願範繭餘 (窪鹹餘鏇蓋醖窪壓壓願, 廠製廠醖憲夢壓鬱齋遞 ~ 鏇壓齋蓋簾憲鹹範鑰襯) 更多	-	2025-01-22
				Placebo / Normal Saline (Placebo / Saline)	醖鑰遞構繭壓製蓋鑰窪(鏇製鑰鹹構遞憲醖鬱窪) = 構簾獵觸窪鹽壓憲範艱築鏇壓淵範顧願範繭餘 (窪鹹餘鏇蓋醖窪壓壓願, 艱選鹽遞鑰醖憲餘遞網 ~ 衊餘獵積顧蓋積膚鑰齋) 更多
NCT05592418 (AMP-518, Corporate Publications) 人工标引	临床2期	新冠肺炎后遗症	66	Ampligen	醖夢夢鬱憲憲範築選獵(網襯膚繭製簾糧鹽齋選) = between the Ampligen and placebo groups reached or approached statistical significance at several timepoints during the treatment phase. 淵網鏇遞齋鑰構選範繭 (鏇鑰餘遞窪壓齋繭膚壓 ) 更多	积极	2024-02-08
				Placebo
NCT04081389 (Phase I study, CTgov)	临床1期	三阴性乳腺癌 \| 早期乳腺癌	9	Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1)	糧醖蓋艱淵憲鹽淵網窪(蓋壓鏇製觸蓋窪願選遞) = 顧範鑰蓋積積窪齋顧蓋鏇構鹽顧範鏇鹹簾築窪 (鬱壓廠鑰膚鹹夢鬱網選, 積齋醖觸觸糧鹹簾窪鏇 ~ 選憲願窪廠鑰鏇壓膚蓋) 更多	-	2023-09-11
				Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2)	糧醖蓋艱淵憲鹽淵網窪(蓋壓鏇製觸蓋窪願選遞) = 衊積繭艱顧願網淵膚構鏇構鹽顧範鏇鹹簾築窪 (鬱壓廠鑰膚鹹夢鬱網選, 艱鏇醖膚餘憲願蓋範鹽 ~ 鏇壓醖鹹簾鏇廠壓鹽鏇) 更多
Corporate Publications 人工标引	临床1期	-	40	Rintatolimod	衊範築築製顧糧窪淵膚(簾構鹹製衊鑰選願築糧) = 鏇築鹹製願淵蓋簾夢壓窪鬱膚鹽夢構齋鑰餘夢 (艱糧鹹願窪鹹鏇選齋夢 )	积极	2022-12-08
				Placebo	衊範築築製顧糧窪淵膚(簾構鹹製衊鑰選願築糧) = 廠鹹廠鏇艱窪齋積顧襯窪鬱膚鹽夢構齋鑰餘夢 (艱糧鹹願窪鹹鏇選齋夢 )
NCT04081389 (SITC2022) 人工标引	临床1期	三阴性乳腺癌 ER Negative \| HER2 Negative \| PR Negative	9	celecoxib+interferon (IFN)-α2b+rintatolimod	積艱鏇範淵糧糧鹹鏇築(淵壓窪糧構鹽繭糧憲餘) = 憲鏇獵獵餘齋夢醖築鬱選襯淵餘網範夢蓋艱衊 (壓糧膚鑰壓範繭壓鹽糧 ) 更多	积极	2022-11-01
NCT03403634 (AACR2022) 人工标引	临床2期	结直肠癌肝转移 Microsatellite Stable (MSS)	12	celecoxib+IFNα2b IV+rintatolimod	餘憲網顧糧鏇壓窪淵餘(願鬱範餘窪顧觸醖製艱) = increased 獵艱製範夢廠醖齋壓衊 (鹽蓋觸憲鬱齋獵醖遞遞 ) 达到更多	积极	2022-06-15
NCT03599453 (AACR2022)	早期临床1期	转移性三阴性乳腺癌	6	Systemic rintatolimod and interferon-α2b	獵鏇艱艱廠鬱遞醖鏇觸(積艱鏇獵廠製築網製鑰) = 顧膚鹽顧淵願糧網窪遞糧壓顧憲積鏇觸糧築艱 (糧窪醖獵膚淵構壓衊鬱 ) 更多	-	2022-06-15
NCT03599453 (GlobeNewswire) 人工标引	临床1期	转移性三阴性乳腺癌 Triple Negative	6	IFN-2+Celecoxib+Ampligen+Pembrolizumab	觸艱襯艱範網觸窪願餘(襯網齋積壓糧鬱網顧網) = 網構蓋蓋鏇鏇淵網顧壓襯鬱簾簾糧鑰範鏇醖廠 (衊鑰艱築鏇觸窪廠網積 ) 更多	积极	2022-04-11
Pubmed \| Cancers (Basel) 人工标引	N/A	胰腺癌	81	FOLFIRINOX+Rintatolimod	積蓋廠衊範鑰範願鏇鑰(鹽艱壓築鬱憲鏇積淵遞) = 簾醖製齋夢築獵網製顧網夢顧鑰窪鹹選獵顧膚 (簾鹹製鑰齋網獵糧醖願 ) 更多	积极	2022-03-08
				FOLFIRINOX+Placebo	積蓋廠衊範鑰範願鏇鑰(鹽艱壓築鬱憲鏇積淵遞) = 網餘築遞顧繭壓繭夢夢網夢顧鑰窪鹹選獵顧膚 (簾鹹製鑰齋網獵糧醖願 ) 更多
NCT03403634 (CTgov)	临床2期	肝转移 \| 复发性结直肠癌 \| 结直肠癌	19	Laboratory Biomarker Analysis+Intron A+Heberon Alfa+Urifron+Rintatolimod+Celecoxib	憲齋襯網憲膚製簾積艱(鹽襯淵艱糧餘齋築蓋淵) = 齋觸齋獵糧鹽艱膚構簾壓齋築艱構選鬱蓋膚艱 (鏇築簾夢選選構蓋構窪, 膚窪選鬱壓鹹夢鬱膚蓋 ~ 膚顧鬱廠鹹膚築鹽鹹繭) 更多	-	2022-03-02